This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -71.43% and -5.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Travere Therapeutics (TVTX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travere Therapeutics (TVTX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -451.16% and -0.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
During Novavax's (NVAX) upcoming fourth-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
What's in the Cards for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) fourth-quarter earnings call, investors are likely to focus on sales number for its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inovio (INO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Inovio's (INO) fourth-quarter earnings call, investor focus will be on updates on the company's progress with the development of its COVID-19 vaccine candidate, INO-4800.
Why Earnings Season Could Be Great for Travere Therapeutics (TVTX)
by Zacks Equity Research
Travere Therapeutics (TVTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Are Options Traders Betting on a Big Move in Travere Therapeutics (TVTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Travere Therapeutics (TVTX) stock based on the movements in the options market lately.
scPharmaceuticals (SCPH) Plunges on Complete Response Letter
by Zacks Equity Research
scPharmaceuticals (SCPH) receives complete response letter from the FDA regarding an NDA for its pipeline candidate, Furoscix, as a potential treatment for congestion due to fluid overload in adult patients.
Reata (RETA) Omaveloxolone Program Faces Delay on FDA Update
by Zacks Equity Research
Reata's (RETA) omaveloxolone development in Friedreich's Ataxia gets delayed further as FDA proposes additional exploratory analyses to support filing regulatory application for its approval.